SUMMARY Cyanosis, clubbing, and arterial oxygen desaturation may occur in patients with liver disease, and are attributed to the presence of pulmonary or peripheral arterio-venous shunting. Cardiac catheterisation and angiocardiography in a patient with a normal heart did not demonstrate the presence of abnormal arterio-venous anastomoses. Pulmonary shunting was proved when intravenous technetiumlabelled macroaggregated albumin, normally held up in capillary networks, was passed quickly through the lungs and immediately detected in high systemic blood flow organs. The opening of peripheral and pulmonary anastomoses in patients with liver disease may be owing to the presence of a vasodilatory substance such as ferritin, which was found to be abnormally increased in the patient's blood.
Blood oxygen desaturation may occur in patients with hepatic disease; it has been attributed to the existence of arterio-venous (A-V) shunts. Radiological confirmation of such A-V shunts in the lungs is extremely difficult. We report on the demonstration of pulmonary A-V fistulae by means of pulmonary radioisotope scanning, using macroaggregated albumin particles. In an attempt to prove the existence of an intrapulmonary right-to-left shunt, a perfusion lung scan using radioactive particles was performed. Immediately after the intravenous administration of 2 mC of technetium-99m-macroaggregated albumin, 20-30 Fm in diameter, a dynamic blood flow study was performed (Figure) , in a sequence of 3 seconds a frame for one minute. Normal intracardiac blood flow was visualised with bilateral lung perfusion. disease and pulmonary and peripheral A-V shunts has led to the hypothesis that the diseased liver releases a vasodilating substance, which opens preexisting, non-functioning precapillary anastomoses in the pulmonary and systemic circulations.8 It has been suggested that this substance is reduced ferritin, a substance released from hypoxic or injured liver, which is known to have a vasodilatory effect, and has been implicated in digital clubbing by virtue of its ability to open precapillary A-V anastomoses in fingers.9 The high ferritin blood levels found in our patient may fit this hypothesis. SUMMARY We investigated the specific H1 receptor antagonist, clemastine, in 15 children with asthma. In the respiratory unit, clemastine was an effective bronchodilator but in a clinical trial we could not show any significant benefit compared with placebo.
Nogrady et al.1 compared a nebulised solution of the specific H1 receptor blocking antihistamine, clemastine, with salbutamol in adult asthmatics. Both drugs produced appreciable bronchodilatation, although the effect with clemastine was of slower onset but of more prolonged action. We have conflicting data on the bronchodilator properties of clemastine.2 3 This trial was designed to assess its clinical role in a group of schoolchildren in whom asthma was poorly controlled on conventional therapy. Patients and methods Fifteen asthmatic children aged 7 years 9 months to 13 years 10 months (mean age 10 years) took part in the study. They were receiving beclomethasone diproprionate (9 children), sodium cromoglycate (3 children), ketotifen (2 children), and oral steroids (one child). All of them were also receiving varying doses of salbutamol by inhalation.
The study design was a crossover trial with 6-week periods on placebo and clemastine, 200 ,ug three times a day, delivered via a metered aerosol, in addition to the child's usual medications. Diary card records were kept of twice-daily peak expiratory flow rate (PEFR), total bronchodilator usage, and asthma symptom scores. The scoring system was a simple one with cough and wheeze graded separately by day and night. No symptoms scored zero and a rising score (up to 3) reflected clinical deterioration. The worst possible daily score was twelve.
At the end of each 6-week treatment period, each child visited the respiratory laboratory with instructions to omit drug therapy for at least 4 hours before attendance. Baseline values were obtained for PEFR, forced expiratory volume in 0-75 seconds (FEVy.75),4 and forced vital capacity, after which each child inhaled two puffs from the metered aerosol used in the previous 6 weeks. Lung function was measured during the next hour, after which a 6-minute run was performed and further readings made during the next 15 minutes. Results were expressed as percentage predicted for height5 and statistical analysis of lung function data was made by paired t tests. The last 28 days of each treatment period was compared-by Wilcoxon's rank sum tests. Results In the respiratory unit, clemastine resulted in significant improvement in PEFR and FEV0.75 compared with initial values (Table 1) . It did not protect against exercised-induced asthma with mean ;P p0.0°compared with initial.
